Wrapmanager Inc. Cuts Stake in Definitive Healthcare Corp. (NASDAQ:DH)

Wrapmanager Inc. lessened its stake in Definitive Healthcare Corp. (NASDAQ:DH) by 7.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 33,767 shares of the company’s stock after selling 2,734 shares during the quarter. Wrapmanager Inc.’s holdings in Definitive Healthcare were worth $336,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Definitive Healthcare in the 3rd quarter worth approximately $116,000. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Definitive Healthcare in the third quarter worth $131,000. Arizona State Retirement System raised its stake in Definitive Healthcare by 13.6% during the fourth quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock valued at $142,000 after purchasing an additional 1,701 shares in the last quarter. Corton Capital Inc. raised its stake in Definitive Healthcare by 17.0% during the third quarter. Corton Capital Inc. now owns 19,964 shares of the company’s stock valued at $160,000 after purchasing an additional 2,898 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Definitive Healthcare by 209.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,209 shares of the company’s stock valued at $161,000 after purchasing an additional 10,977 shares during the last quarter. Institutional investors own 98.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on DH shares. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Definitive Healthcare from $10.00 to $7.00 and set a “hold” rating on the stock in a research report on Thursday. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research report on Wednesday. Barclays dropped their target price on Definitive Healthcare from $11.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday. Canaccord Genuity Group decreased their price target on Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, Stifel Nicolaus dropped their price objective on shares of Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a research note on Wednesday. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.94.

Definitive Healthcare Trading Down 3.4 %

Shares of NASDAQ DH traded down $0.18 during mid-day trading on Thursday, reaching $5.17. The company had a trading volume of 3,323,524 shares, compared to its average volume of 643,916. Definitive Healthcare Corp. has a 52 week low of $4.38 and a 52 week high of $12.45. The business’s 50-day moving average is $7.61 and its 200-day moving average is $8.27. The stock has a market cap of $608.97 million, a price-to-earnings ratio of -2.90, a price-to-earnings-growth ratio of 6.12 and a beta of 1.41. The company has a current ratio of 2.31, a quick ratio of 2.31 and a debt-to-equity ratio of 0.20.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The company had revenue of $65.93 million for the quarter, compared to analysts’ expectations of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. Equities analysts expect that Definitive Healthcare Corp. will post 0.11 earnings per share for the current year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.